Enanta Pharmaceuticals (ENTA) Interest Expenses (2012 - 2026)
Enanta Pharmaceuticals' (ENTA) quarterly Interest Expenses came in at $7.7 million in Q1 2026, up 348.72% YoY from $1.7 million in Q1 2025, and up 149.46% on a QoQ basis from $3.1 million in Q4 2025.
Enanta Pharmaceuticals (ENTA) Interest Expenses (2012 - 2026) Analysis & Trends
Enanta Pharmaceuticals (ENTA) has 15 years of Interest Expenses data on file, last reported at $7.7 million in Q1 2026.
- Quarterly Interest Expenses rose 348.72% year-over-year to $7.7 million in Q1 2026, while the trailing twelve-month figure through Mar 2026 was $7.7 million (down 80.32% YoY) and the FY2025 annual result came in at $142.2 million, up 1114.63% from the prior year.
- Interest Expenses advanced to $7.7 million in Q1 2026, from $3.1 million in the prior quarter.
- In the past five years, Interest Expenses ranged from a high of $113.9 million in Q2 2022 to a low of $1.7 million in Q1 2025.
- A 5-year average of $27.1 million and a median of $7.7 million in 2026 frame the typical range for Interest Expenses.
- Annual changes were most pronounced in 2023 — Interest Expenses plunged 98.25% — and 2024, when it surged 1591.84%.
- Tracing ENTA's Interest Expenses over 5 years: stood at $17.6 million in 2022, then plunged by 80.5% to $3.4 million in 2023, then slipped by 12.58% to $3.0 million in 2024, then gained by 2.49% to $3.1 million in 2025, then jumped by 149.46% to $7.7 million in 2026.
- The last three Interest Expenses figures came in at $7.7 million (Q1 2026), $3.1 million (Q4 2025), and $8.3 million (Q3 2025), per Business Quant data.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Int Expense (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 128.13 Bn | 120.28 Bn | 2.84 Bn | 439.40 Mn |
| 2 | Regeneron Pharmaceuticals | 112.33 Bn | 104.33 Bn | 3.93 Bn | 52.50 Mn |
| 3 | Argenx Se | 53.24 Bn | 48.05 Bn | 1.41 Bn | - |
| 4 | Revolution Medicines | 43.64 Bn | 43.64 Bn | - | 2.70 Bn |
| 5 | BeOne Medicines | 39.27 Bn | 34.17 Bn | 1.53 Bn | 39.74 Mn |
| 6 | MindWalk Holdings | 35.32 Bn | 35.31 Bn | 1.82 Bn | 335,572.77 |
| 7 | Royalty Pharma | 33.72 Bn | 35.84 Bn | - | 218.10 Mn |
| 8 | Alnylam Pharmaceuticals | 30.58 Bn | 27.27 Bn | 992.69 Mn | 82.05 Mn |
| 9 | Insmed | 27.01 Bn | 25.85 Bn | 358.27 Mn | 20.27 Mn |
| 10 | Enanta Pharmaceuticals | 383.29 Mn | 193.78 Mn | - | 12.57 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Jun 30, 2026 | 12.57 Mn |
| Jun 30, 2026 | 12.57 Mn |
| Mar 31, 2026 | 7.69 Mn |
| Mar 31, 2026 | 7.69 Mn |
| Dec 31, 2025 | 3.08 Mn |
| Dec 31, 2025 | 3.08 Mn |
| Sep 30, 2025 | 8.28 Mn |
| Sep 30, 2025 | 8.28 Mn |
| Jun 30, 2025 | 88.19 Mn |
| Jun 30, 2025 | 88.19 Mn |
| Mar 31, 2025 | 1.71 Mn |
| Mar 31, 2025 | 1.71 Mn |
| Dec 31, 2024 | 3.01 Mn |
| Dec 31, 2024 | 3.01 Mn |
| Sep 30, 2024 | 2.43 Mn |
| Sep 30, 2024 | 2.43 Mn |
| Jun 30, 2024 | 33.79 Mn |
| Jun 30, 2024 | 33.79 Mn |
| Mar 31, 2024 | 31.94 Mn |
| Mar 31, 2024 | 31.94 Mn |